Number of pages: 100 | Report Format: PDF | Published date: April 12, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
According to the deep-dive market assessment study by Growth Plus Reports, the global human chorionic gonadotropin market was valued at US$ 695.2 million in 2022 and is expected to register a revenue CAGR of 7.10% to reach US$ 1,288.9 million by 2031.
Human Chorionic Gonadotropin Market Fundamentals
The placenta naturally produces human chorionic gonadotropin (HCG) hormone during pregnancy. It is also produced in smaller quantities by the pituitary gland in both men and women. HCG plays a critical role in pregnancy by stimulating the production of other hormones, such as estrogen and progesterone, which help to maintain the pregnancy. It is also responsible for preventing the breakdown of the corpus luteum, which is essential to produce progesterone in early pregnancy. In addition to its role in pregnancy, HCG has been used for various medical purposes. In men, HCG can stimulate the production of testosterone, which can be helpful in the treatment of hypogonadism. In women, HCG can induce ovulation and increase the chances of conception in cases of female infertility. HCG is available in various forms, including injections, tablets, and oral drops. In some cases, it is also used as a weight loss supplement, although limited scientific evidence supports its effectiveness for this purpose.
Human Chorionic Gonadotropin Market Dynamics
Infertility is a growing concern globally, and HCG is commonly prescribed for treating infertility in both men and women. The increasing prevalence of infertility is expected to boost the demand for HCG in the coming years and thus help in the growth of the global human chorionic gonadotropin market. For instance, according to WHO, infertility is a global health issue affecting millions of people of reproductive age worldwide. The available data suggests that one in every six people may suffer infertility in their lifetime. Additionally, HCG-based pregnancy tests are widely used due to their accuracy and ease of use. The increasing awareness about the benefits of early pregnancy detection is expected to drive the demand for HCG-based pregnancy tests. HCG is also used for weight loss in combination with a low-calorie diet. The growing awareness about the benefits of HCG in weight loss is also expected to fuel the demand for HCG. Moreover, HCG is also used to treat certain types of cancer, including testicular, ovarian, and bladder. The increasing adoption of HCG in cancer treatment will help grow the global human chorionic gonadotropin market.
However, HCG can cause side effects such as headache, irritability, fatigue, and fluid retention. It can also cause more severe side effects in rare cases, such as ovarian hyperstimulation syndrome (OHSS). These side effects can limit the use of HCG and may negatively impact the market revenue growth. Furthermore, there are alternative treatments available for infertility, weight loss, and cancer treatment that may limit the demand. For example, there are several other fertility treatments available such as in vitro fertilization (IVF), that may be preferred over HCG in some cases. Additionally, the lack of reimbursement policies in developing nations and limited awareness about HCG-based treatments are some of the restraints impeding the overall market growth.
Human Chorionic Gonadotropin Market Ecosystem
The global human chorionic gonadotropin market is analyzed from four perspectives: product, application, end-user, and region.
Human Chorionic Gonadotropin Market by Product
Based on the product, the global human chorionic gonadotropin market is segmented into naturally extracted and recombinant.
The naturally extracted segment dominated the market with the principal revenue share in 2022, attributed to rising awareness of natural and organic products. HCG is extracted from natural sources, such as the urine of pregnant women. Naturally extracted HCG is the traditional form of HCG and has been used for several decades. It has higher purity and is less likely to cause adverse reactions as it is derived from human sources. The natural human chorionic gonadotropin has also been found to be more effective in certain medical applications, such as in the treatment of female infertility. The increasing demand for natural and organic products in the healthcare industry is also expected to drive the revenue growth of the naturally extracted HCG segment. These factors contribute to the revenue growth of the naturally extracted segment.
The recombinant segment also accounted for a significant revenue share of the market. HCG is produced using recombinant DNA technology. Recombinant HCG is a synthetic form of HCG that is produced in a laboratory using genetically engineered cells. It is designed to mimic the actions of natural HCG in the body. It has the same structure and function as natural HCG and is used for the same medical purposes, such as in fertility treatments and the treatment of hypogonadism. Additionally, the recombinant HCG has some advantages, such as it is produced using a controlled manufacturing process, which ensures that the final product has consistent potency and purity. It can be produced in larger quantities, which makes it easier to meet the demand for HCG-based treatments. These factors contribute to the revenue growth of the recombinant segment.
Human Chorionic Gonadotropin Market by Application
Based on the application, the global human chorionic gonadotropin market is segmented into male hypogonadism, female infertility treatment, oligospermic treatment, and others.
The male hypogonadism segment also accounted for a sizable revenue share, owing to the increasing prevalence of male hypogonadism, the rising awareness about HCG-based treatments, and the availability of advanced healthcare facilities. Male hypogonadism is a condition in which the testes do not produce enough testosterone. HCG is used in male hypogonadism treatment to stimulate the production of testosterone, which can help improve the symptoms associated with low testosterone levels. HCG-based treatments are more common in male hypogonadism, as they can stimulate the production of testosterone and improve the symptoms associated with low testosterone levels, such as decreased libido, fatigue, and muscle weakness. These overall factors contribute to the revenue growth of the male hypogonadism segment.
Human Chorionic Gonadotropin Market by End User
Based on the end user, the global human chorionic gonadotropin market is segmented into fertility clinics, research institutions, and others.
The fertility clinics segment is a key player in the human chorionic gonadotropin market, with the largest revenue share in 2022, owing to being a primary place to visit for fertility issues. Fertility clinics provide assistive reproduction treatments, such as in vitro fertilization (IVF), intrauterine insemination (IUI), and ovulation induction. HCG is used in these treatments to trigger ovulation and improve the chances of conception. These clinics provide specialized care to couples and individuals having trouble conceiving a child and maintaining pregnancy. HCG is often used as part of fertility treatment protocols in these clinics. Fertility clinics also play an important role in monitoring patients undergoing HCG treatment. They monitor hormone levels, follicle development, and the timing of ovulation to optimize the chances of successful conception. In addition, fertility clinics provide counseling and support to patients undergoing fertility treatments, which can be emotionally challenging. They also offer a range of other services, including genetic testing, donor sperm and eggs, and surrogacy. These overall factors contribute to the revenue growth of the fertility clinics segment.
The research institutions also accounted for a prominent revenue share in the market, owing to various research and development activities carried out by the research institutes. HCG is used in research to understand its mechanism of action and to develop new treatments and therapies for various medical conditions. Researchers use HCG to study its effects on various physiological processes and to develop new therapies for conditions such as female infertility, male infertility, and certain types of cancer.
Human Chorionic Gonadotropin Market by Region
Geographically, the global human chorionic gonadotropin market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.
North America dominated the global human chorionic gonadotropin market with the largest revenue share in 2022, attributed to well-established healthcare infrastructure, attractive reimbursement regulations, and the region's rising infertility burden. Additionally, companies across the region are continuously working on launching new and innovative which is also helping in improving the human chorionic gonadotropin market outlook. For instance, in February 2021, Pfizer Inc. and OPKO Health Inc. received validation from the European Medicines Agency (EMA) to review the Marketing Authorization Application (MAA) for somatrogon, a long-acting recombinant human growth hormone. This hormone is designed to be administered once weekly to treat growth hormone deficiency (GHD) in pediatric patients. Somatrogon is an investigational biologic product that contains glycosylated human growth hormone and one copy of the C-terminal peptide (CTP) from the beta chain of human chorionic gonadotropin at the N-terminus and two copies of CTP (in tandem) at the C-terminus. Somatrogon was designated an Orphan Drug in the United States and the European Union to treat growth hormone deficiency.
Competitive Landscape of the Global Human Chorionic Gonadotropin
The prominent players operating in the global human chorionic gonadotropin market are:
Strategic Developments in Human Chorionic Gonadotropin
Human chorionic gonadotropin (HCG) is naturally produced in the placenta and stimulates the corpus luteum to produce progesterone to maintain pregnancy.
The expected size of the global human chorionic gonadotropin market in 2031 is US$ 1,288.9 million.
The expected revenue CAGR of the human chorionic gonadotropin market during the forecast period will be 7.1% from 2023 to 2031.
The lack of reimbursement policies in developing nations and limited awareness about HCG-based treatments restrict the global human chorionic gonadotropin market growth to its full potential.
The prominent players operating in the global human chorionic gonadotropin market are Cipla Limited, Intas Pharmaceuticals Ltd., Lupin Limited, Biocare Medical LLC, Fresenius Kabi AG, Prospec-Tany Techno Gene Ltd., and Lee BioSolutions Inc.
*Insights on financial performance are subject to the availability of information in the public domain